6-K - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
EFFECT - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
F-3/A - CASI Pharmaceuticals, Inc. (0001962738) (Filer)
BEIJING, Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City. Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1x1 investor meetings at the conference.
BEIJING, Aug. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024. "The second quarter of 2024 was a period of significant progress for CASI as we shifted our Company's strategy to the development of therapeutics for organ transplant rejection and autoimmune disease," said Dr. Wei-Wu He,
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical deve
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M MEDS: 34% | TRxADE HEALTH shares are trading higher. The company reported Q1 financial results. RXRX: -21% | Recursion Pharmaceuticals Announced The Pricing Of Its Underwritten Public Offering Of 30,769,230 Shares Of Its Class A Common Stock At A Price To The Public Of $6.50 Per Share
SC 13D/A - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
SC 13G - CASI Pharmaceuticals, Inc. (0001962738) (Subject)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
4 - CASI Pharmaceuticals, Inc. (0000895051) (Issuer)
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe
BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.
BEIJING, July 8, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capi
BTIG Research initiated coverage of CASI Pharma with a rating of Buy and set a new price target of $4.00
HC Wainwright & Co. reiterated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.50 previously
Mizuho initiated coverage of CASI Pharmaceuticals with a rating of Buy and set a new price target of $3.80